Global Biosimilars Treatment Market, 2025-2035
The global biosimilars treatment market is characterized by robust growth, driven by increasing adoption of cost-effective biologic therapies and patent expirations of blockbuster drugs. Biosimilars, developed as highly similar alternatives to original biologic medicines, offer comparable safety, efficacy, and quality, presenting a valuable solution for healthcare systems managing chronic and life-threatening diseases. This comprehensive evaluation covers market segmentation by type, application, technology, distribution channel, and organization size, alongside regional and company landscape from 2020 to 2035.
Latest Market Dynamics
Key Drivers
- Patent expirations of major biologic drugs have created significant opportunities for biosimilar manufacturers, spurring rapid market entry and competition. In 2024, Amgen launched a biosimilar for Humira in the US, exemplifying this trend.
- Escalating demand for cost-effective treatments in chronic diseases such as cancer and diabetes is driving biosimilar uptake. Biocon reported a surge in biosimilar revenue in early 2024, reflecting growing healthcare provider and patient acceptance.
Key Trends
- Strategic collaborations between biotech firms and pharmaceutical giants to accelerate biosimilar pipelines. For instance, Samsung Bioepis and Organon broadened their biosimilar portfolio with new approvals in 2024.
- Increased regulatory approvals across major markets, with EU and FDA expediting review processes for biosimilars as of 2024, fostering competition and faster product availability.
Key Opportunities
- Expanding market access in emerging economies, where healthcare systems seek affordable biologic therapies. Biocon has rapidly scaled operations in Southeast Asia and Latin America in 2024.
- Digital transformation in biosimilar supply chains and e-pharmacies enables wider distribution and patient outreach, as seen with Sandoz partnering with major online platforms in 2024.
Key Challenges
- Market acceptance barriers among clinicians and patients remain, with ongoing education needed on biosimilar equivalence. Pfizer has initiated global campaigns to address these in 2024.
- Complex and evolving regulatory requirements across geographies increase development timelines and costs, affecting companies like Teva Pharmaceutical in 2024.
Key Restraints
- Intellectual property litigation is a persistent challenge, delaying launch timelines. Novartis encountered biosimilar launch delays in the US due to patent disputes in 2024.
- Manufacturing complexity and stringent comparability requirements escalate production costs, limiting the entry of smaller players. Mylan faced increased COGS during new biosimilar launches in early 2024.
Global Biosimilars Treatment Market Share (%), By Type, 2025
Monoclonal antibodies dominate the biosimilars market due to their extensive use in oncology, autoimmune, and other chronic diseases. Recombinant hormones and insulins are also significant, addressing endocrine and metabolic disorders. The market landscape in 2025 sees monoclonal antibodies at the forefront, driven by multiple product launches, while recombinant hormones and fusion proteins also hold notable shares. This composition reflects the broadening therapeutic applications and increasing confidence in biosimilars across major disease areas.
Global Biosimilars Treatment Market Share (%), By Application, 2025
The oncology segment leads the biosimilars treatment market, capturing the largest share in 2025 as biosimilars offer critical cost savings in cancer care. Autoimmune disease treatments follow, facilitated by developed biosimilar portfolios for conditions like rheumatoid arthritis. Chronic diseases, blood disorders, and infectious diseases represent growing applications, signaling biosimilars’ expanding impact in various therapeutic realms.
Global Biosimilars Treatment Market Revenue (USD Million), 2020-2035
The global biosimilars treatment market is forecast to grow from 17,550 Million in 2020 to 65,900 Million by 2035. Revenue growth is propelled by patent expirations, increased chronic disease burden, and accelerated regulatory approvals. The period between 2025 and 2030 is marked by steeper growth as new biosimilar entrants and expanded indications fuel adoption. By 2035, the market is expected to reach unprecedented levels due to wider global access and technological advancements.
Global Biosimilars Treatment Market YOY Growth (%), 2020-2035
Year-over-year growth rates for the global biosimilars treatment market peak in the years following key biosimilar drug exclusivities and major regulatory approvals. A strong surge from 2024 to 2027 is observed, with YOY growth stabilizing at high single digits by 2030 as the market matures and becomes more competitive, reflecting the sector’s promising outlook.
Global Biosimilars Treatment Market Share (%), By Region, 2025
Europe leads the global biosimilars treatment market in 2025 due to supportive regulatory environments and high biosimilar uptake. North America holds the second-largest share as more biosimilars enter the US market post-patent expiry. APAC continues to expand rapidly, driven by increased healthcare access and lower-cost production. Latin America, MEA, and Africa are emerging regions with growing biosimilar adoption.
Global Biosimilars Treatment Market Players Share (%), 2025
The global biosimilars market is fragmented with top players holding substantial, yet competitive shares. Pfizer leads the market in 2025, followed by Novartis (Sandoz) and Amgen, which have robust portfolios and global reach. Biocon, Celltrion, and Samsung Bioepis are major contributors, reflecting the mix of established pharma and specialized biotechs in driving innovation and access.
Global Biosimilars Treatment Market Buyers Share (%), 2025
Hospital pharmacies are the primary buyers of biosimilars, accounting for the largest share in 2025 due to institutional procurement for major chronic and acute care needs. Retail pharmacies are gaining traction as biosimilars enter outpatient settings, while online pharmacies increasingly play a role in distribution, reflecting changing healthcare delivery trends.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 30600 |
| Regions | North America, Europe, APAC, Latin America, Middle East & Africa |
| Segments | Monoclonal Antibodies, Recombinant Hormones, Fusion Proteins, Immunomodulators, Insulins, Erythropoietin, Oncology, Autoimmune Diseases, Chronic Diseases, Blood Disorders, Infectious Diseases, Other Applications |
| Players | Pfizer Inc., Novartis AG, Amgen Inc., Biocon Limited, Celltrion Healthcare, Samsung Bioepis, Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck & Co., Inc., Sandoz International GmbH, Hospira, Inc., Dr. Reddy's Laboratories, Boehringer Ingelheim, Biogen Inc. |
Key Recent Developments
- June 2024: Amgen launched Amjevita, a biosimilar to Humira, in the US, expanding its biosimilars portfolio.
- July 2024: Sandoz received FDA approval for a biosimilar pegfilgrastim, strengthening its leading position in the US biosimilars market.
- August 2024: Biocon received marketing authorization for insulin glargine in the European Union, furthering its EU expansion.
- September 2024: Pfizer announced a global awareness initiative to support biosimilar adoption among healthcare professionals.
- October 2024: Celltrion Healthcare signed a cross-border distribution agreement with a Latin American healthcare group to boost biosimilar access.
